Dr. Jay Spiegel (IMAGE)

University of Miami Miller School of Medicine

Dr. Jay Spiegel

Caption

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive lymphoma. The early findings will be presented Dec. 8 at ASH by Jay Spiegel, M.D., a transplant and cellular therapy physician at Sylvester Comprehensive Cancer Center.

Credit

Sylvester Comprehensive Cancer Center

Usage Restrictions

Use with attribution

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.